4.6 Article

Charcot-Marie-Tooth disease: Emerging mechanisms and therapies

期刊

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2012.04.020

关键词

Charcot-Marie-Tooth disease (CMT); Axonal transport; Histone deacetylase 6 (HDAC6)

资金

  1. Fund for Scientific Research Flanders (FWO)
  2. University of Leuven
  3. Belgian government [P6/43]
  4. Association Beige contre les Maladies neuro-Musculaires (ABMM)
  5. Association Francaise contre les Myopathies (AFM)
  6. Frick Foundation for Amyotrophic Lateral Sclerosis Research
  7. Muscular Dystrophy Association (MDA)
  8. European Community [259867]
  9. Latran Foundation
  10. Agency for Innovation by Science and Technology in Flanders (IWT-Vlaanderen)

向作者/读者索取更多资源

Charcot-Marie-Tooth disease is the most common inherited disorder of the peripheral nervous system. The disease is characterized by a progressive muscle weakness and atrophy, sensory loss, foot (and hand) deformities and steppage gait. While many of the genes associated with axonal CMT have been identified, to date it is unknown which mechanism(s) causes the disease. However, genetic findings indicate that the underlying mechanisms mainly converge to the axonal cytoskeleton. In this review, we will summarize the evidence for this pathogenic convergence. Furthermore, recent work with new transgenic mouse models has led to the identification of histone deacetylase 6 as a potential therapeutic target for inherited peripheral neuropathies. This enzyme deacetylates microtubules and plays a crucial role in the regulation of axonal transport. These findings offer new perspectives for a potential therapy to treat axonal Charcot-Marie-Tooth disease and other neurodegenerative disorders characterized by axonal transport defects. (C) 2012 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据